Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Up – Here’s What Happened

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) shares gapped up before the market opened on Thursday. The stock had previously closed at $16.60, but opened at $17.30. Daiichi Sankyo shares last traded at $16.93, with a volume of 75,355 shares traded.

Analyst Ratings Changes

DSNKY has been the topic of a number of analyst reports. Zacks Research upgraded shares of Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a research note on Monday, September 21st. Jefferies Financial Group lowered shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a report on Thursday, July 30th. Two research analysts have rated the stock with a Hold rating. According to MarketBeat.com, the stock currently has a consensus rating of “Hold”.

Daiichi Sankyo Trading Up 2.2%

The company has a current ratio of 2.92, a quick ratio of 1.96 and a debt-to-equity ratio of 0.29. The firm has a market capitalization of $32.00 billion, a P/E ratio of 19.98, a P/E/G ratio of 1.79 and a beta of -0.11. The firm has a 50-day moving average of $17.80 and a two-hundred day moving average of $17.18.

Daiichi Sankyo (OTCMKTS:DSNKY) last released its earnings results on Friday, July 31st. The company reported $0.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The business had revenue of $3.61 billion during the quarter, compared to the consensus estimate of $3.32 billion. Daiichi Sankyo had a net margin of 10.92% and a return on equity of 14.35%. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. On average, analysts anticipate that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.93 EPS for the current year.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a Japan-based pharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. Its business is centered on oncology, with additional operations in areas such as cardiovascular disease, immunology, and other serious medical conditions.

The company’s oncology portfolio includes antibody-drug conjugates, a technology designed to deliver potent cancer treatments more selectively to tumor cells. Daiichi Sankyo develops and commercializes medicines independently and through collaborations, including its partnership with AstraZeneca on trastuzumab deruxtecan, marketed as Enhertu, for certain cancer indications.

Daiichi Sankyo was formed in 2005 through the merger of Daiichi Pharmaceutical and Sankyo.